X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/03/28/2854508/16626/en/Zevra-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Updates.html
https://www.prnewswire.com/news-releases/journal-frontiers-in-psychiatry-publishes-analysis-of-open-label-safety-study-showing-improvements-in-sleep-habits-for-children-with-adhd-after-treatment-with-azstarys-serdexmethylphenidate-and-dexmethylphenidate-301862645.html
https://www.prnewswire.com/news-releases/coriums-novel-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-had-no-clinically-significant-impact-on-childrens-weight-and-height-growth-rate-301830739.html
https://www.prnewswire.com/news-releases/coriums-novel-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-shown-safe-and-effective-in-long-term-study-301752562.html
https://www.globenewswire.com/news-release/2022/11/18/2559035/16626/en/KemPharm-Receives-FDA-Orphan-Drug-Designation-for-Serdexmethylphenidate-SDX-for-the-Treatment-of-Idiopathic-Hypersomnia-IH.html
https://www.prnewswire.com/news-releases/corium-to-present-positive-data-on-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-and-alzheimers-disease-medication-adlarity-donepezil-transdermal-system-at-psych-congress-2022-301622663.html
https://www.biospace.com/article/releases/serdexmethylphenidate-a-prodrug-of-dexmethylphenidate-and-contained-in-corium-s-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-has-low-relative-potential-for-abuse/
https://www.prnewswire.com/news-releases/corium-to-present-at-academy-of-managed-care-pharmacy-fast-acting-azstarys-serdexmethylphenidate-and-dexmethylphenidate-significantly-improves-attention-and-behavior-in-children-aged-6-to-12-years-with-adhd-301511349.html
https://www.globenewswire.com/news-release/2022/03/21/2406583/16626/en/KemPharm-Announces-Full-Data-Set-from-Higher-Dose-Serdexmethylphenidate-SDX-Phase-1-Clinical-Trial.html
https://www.globenewswire.com/news-release/2022/01/11/2364742/16626/en/KemPharm-Announces-Research-Involving-Serdexmethylphenidate-to-be-Featured-in-Two-Poster-Presentations-at-the-APSARD-2022-Annual-Conference.html
https://www.asiaone.com/business/ark-biopharmaceutical-enters-exclusive-license-agreement-novel-adhd-treatment-azstarys
https://www.prnewswire.com/news-releases/significant-adhd-symptom-improvement-with-30-minute-onset-and-13-hour-duration-of-efficacy-delivered-by-once-daily-corium-product-azstarys-serdexmethylphenidate-and-dexmethylphenidate-in-children-ages-6-to-12-years-301411981.html
https://www.globenewswire.com/news-release/2021/10/20/2317276/16626/en/KemPharm-Announces-Research-Involving-AZSTARYS-and-Serdexmethylphenidate-to-be-Featured-in-Poster-Presentations-at-Multiple-Medical-Conferences-during-ADHD-Awareness-Month-October.html
https://www.prnewswire.com/news-releases/once-daily-azstarys-serdexmethylphenidate-and-dexmethylphenidate-first-and-only-product-containing-dexmethylphenidate-prodrug-for-adhd-in-patients-aged-6-years-and-older-significantly-reduces-adhd-symptoms-301399896.html
https://www.prnewswire.com/news-releases/corium-secures-235-million-in-debt-financing-301384817.html
https://www.globenewswire.com/news-release/2021/03/03/2185820/0/en/KemPharm-Announces-FDA-Approval-of-AZSTARYS-serdexmethylphenidate-and-dexmethylphenidate-capsules-for-oral-use-CII-A-New-Once-Daily-Treatment-for-ADHD.html
https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-novel-once-daily-capsule-azstarys-serdexmethylphenidate-and-dexmethylphenidate-first-and-only-product-containing-dexmethylphenidate-prodrug-for-adhd-in-patients-age-6-years-and-older-301240023.html
Market Place
Share 
